Protocol summary

Study aim
Investigating the effect and side effects of bupropion on fatigue, disability and quality of life of multiple sclerosis patients
Design
A controlled, parallel-group, double-blind, randomized, phase 2 clinical trial on 100 patients. Blocks of four will be used for randomization.
Settings and conduct
This study is a randomized clinical trial (blocks of four), double blind (participants and results analyzer), with parallel groups, without a control group and with the participation of 80 patients with multiple sclerosis referred to Imam Reza Hospital (Tabriz). will be done. In this study, the effects and complications of bupropion in patients will be investigated.
Participants/Inclusion and exclusion criteria
The most important criteria for entering the study include a definitive diagnosis of multiple sclerosis based on the MacDonald criteria, 2017 version, and an EDSS value of less than four, and the most important exclusion criteria include: the use of drugs that have a reducing or intensifying effect on fatigue, such as dalfampridine, modafinil, anti Depressants and other psychiatric drugs and the use of other auxiliary methods such as herbal medicines, antidepressants, yoga, unnecessary supplements, addiction or drug use.
Intervention groups
In this study, patients who will refer to the doctor due to multiple sclerosis will undergo intervention. Patients will be randomly divided into two groups. For one group, along with routine treatments, Bupropion drug will be prescribed and for another group, placebo drug will be prescribed along with routine drugs, and finally, the level of fatigue and quality of life will be compared in them.
Main outcome variables
Quality of life

General information

Reason for update
Acronym
IRCT registration information
IRCT registration number: IRCT20190325043107N48
Registration date: 2024-08-10, 1403/05/20
Registration timing: prospective

Last update: 2024-08-10, 1403/05/20
Update count: 0
Registration date
2024-08-10, 1403/05/20
Registrant information
Name
Mehdi Khanbabayi Gol
Name of organization / entity
Country
Iran (Islamic Republic of)
Phone
+98 41 3334 7054
Email address
khanbabayimehdi69@gmail.com
Recruitment status
Recruitment complete
Funding source
Expected recruitment start date
2024-10-21, 1403/07/30
Expected recruitment end date
2025-03-18, 1403/12/28
Actual recruitment start date
empty
Actual recruitment end date
empty
Trial completion date
empty
Scientific title
Investigating the effect and side effects of bupropion on fatigue, disability and quality of life of multiple sclerosis patients
Public title
Investigating the effects and side effects of bupropion in multiple sclerosis patients
Purpose
Treatment
Inclusion/Exclusion criteria
Inclusion criteria:
Definitive diagnosis of multiple sclerosis based on MacDonald criteria 2017 version EDSS value smaller than four
Exclusion criteria:
Taking drugs that have a reducing or intensifying effect on fatigue, such as dalfampridine, modafinil, antidepressants and other psychiatric drugs. Using other auxiliary methods such as herbal medicines, antidepressants, yoga, unnecessary supplements, addiction or drug use
Age
From 18 years old to 65 years old
Gender
Both
Phase
2-3
Groups that have been masked
  • Participant
  • Data analyser
Sample size
Target sample size: 80
Randomization (investigator's opinion)
Randomized
Randomization description
In this study, with a sample size of 80, we use the patients using the block permutation randomization method, which is used in this method to balance the number of allocated samples, and with 4 people in each block. We assemble the possible blocks as follows. block 1: BBAA, block 2: AABB, block 3: ABAB, block 4: BABA, block 5: ABBA, and block 6: BAAB, we need 20 blocks for 80 people. It is random in the block method. We choose numbers from one to six. For example, if number 6 is chosen as the first block and number 2 as the second block, the people who enter the study will be given BAABAABB in order from left to right. and finally they will divid into two intervention groups (group A) and control group (group B).
Blinding (investigator's opinion)
Double blinded
Blinding description
The thesis results analyst who will analyze the expected result and also the participants will be unaware of the type of procedure performed and will be blind during the study; Therefore, this study will be conducted in a double-blind manner. Since the participants will be unaware of the type of technique used, in this study they will not know what type of technique will be used in other patients.
Placebo
Used
Assignment
Parallel
Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee
Name of ethics committee
Ethics committee of Tabriz University of Medical Sciences
Street address
Imam Reza Hospital, Azadi Ave
City
Tabriz
Province
East Azarbaijan
Postal code
5165665631
Approval date
2024-07-21, 1403/04/31
Ethics committee reference number
IR.TBZMED.REC.1403.338

Health conditions studied

1

Description of health condition studied
Quality of life
ICD-10 code
G35
ICD-10 code description
Multiple sclerosis

Primary outcomes

1

Description
Quality of life
Timepoint
Once every month for six months
Method of measurement
McGill Quality of Life Questionnaire

2

Description
Fatigue
Timepoint
Once every month for six months
Method of measurement
Physical examination and asking the patient himself

3

Description
Disability
Timepoint
Once every month for six months
Method of measurement
Physical examination and asking the patient himself

Secondary outcomes

empty

Intervention groups

1

Description
Intervention group: The patients of this group will be prescribed bupropion (150 mg/extended release product of Obidi company) once a day for six months in addition to routine treatments, and finally the quality of life (measured using the McGill Quality of Life Questionnaire) and fatigue. and disability (measurement in the form of physical examination and questions from the patient himself) will be measured once a month for six months.
Category
Treatment - Drugs

2

Description
Control group: Patients of this group will be prescribed placebo (the same color, shape and size of the intervention group pills) once a day for six months in addition to the routine treatments, and finally the quality of life (measured with the help of the McGill Quality of Life Questionnaire) ) and fatigue and disability (measured by physical examination and asking the patient himself) will be measured once a month for six months.
Category
Treatment - Drugs

Recruitment centers

1

Recruitment center
Name of recruitment center
Imam Reza Hospital
Full name of responsible person
Samaneh Hosseini
Street address
Imam Reza Hospital, Azadi Ave
City
Tabriz
Province
East Azarbaijan
Postal code
6165665631
Phone
+98 41 3335 5921
Email
Drvaez@yahoo.com

Sponsors / Funding sources

1

Sponsor
Name of organization / entity
Tabriz University of Medical Sciences
Full name of responsible person
Abolghasem Jouyban
Street address
Imam Reza Hospital, Azadi Ave
City
Tabriz
Province
East Azarbaijan
Postal code
5165665631
Phone
+98 41 3335 7310
Email
Ajouyban@hotmail.com
Grant name
Grant code / Reference number
Is the source of funding the same sponsor organization/entity?
Yes
Title of funding source
Tabriz University of Medical Sciences
Proportion provided by this source
100
Public or private sector
Public
Domestic or foreign origin
Domestic
Category of foreign source of funding
empty
Country of origin
Type of organization providing the funding
Academic

Person responsible for general inquiries

Contact
Name of organization / entity
Tabriz University of Medical Sciences
Full name of responsible person
Rana Malek_Mohammadi
Position
Clinical specialty assistant
Latest degree
Medical doctor
Other areas of specialty/work
Neuroscience
Street address
Imam Reza Hospital, Azadi Ave
City
Tabriz
Province
East Azarbaijan
Postal code
5165665631
Phone
+98 41 3335 7310
Email
Mkhanbabayi@yahoo.com

Person responsible for scientific inquiries

Contact
Name of organization / entity
Tabriz University of Medical Sciences
Full name of responsible person
Mehdi Khanbabayi Gol
Position
MSc in Nursing Education
Latest degree
Master
Other areas of specialty/work
Nursery
Street address
Imam Reza Hospital, Azadi Ave
City
Tabriz
Province
East Azarbaijan
Postal code
5981764863
Phone
+98 41 3334 7054
Fax
Email
Khanbabayimehdi69@gmail.com

Person responsible for updating data

Contact
Name of organization / entity
Tabriz University of Medical Sciences
Full name of responsible person
Mehdi Khanbabayi Gol
Position
MSc in Nursing Education
Latest degree
Master
Other areas of specialty/work
Nursery
Street address
Imam Reza Hospital, Azadi Ave
City
Tabriz
Province
East Azarbaijan
Postal code
5981764863
Phone
+98 41 3334 7054
Fax
Email
Khanbabayimehdi69@gmail.com

Sharing plan

Deidentified Individual Participant Data Set (IPD)
Undecided - It is not yet known if there will be a plan to make this available
Study Protocol
Undecided - It is not yet known if there will be a plan to make this available
Statistical Analysis Plan
Undecided - It is not yet known if there will be a plan to make this available
Informed Consent Form
Undecided - It is not yet known if there will be a plan to make this available
Clinical Study Report
Undecided - It is not yet known if there will be a plan to make this available
Analytic Code
Undecided - It is not yet known if there will be a plan to make this available
Data Dictionary
Undecided - It is not yet known if there will be a plan to make this available
Loading...